Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C138997
http://purl.obolibrary.org/obo/NCIT_C138997
|
|---|---|
| Preferred Name | Anlotinib |
| Definitions |
A receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth. |
|---|---|
| prefLabel | Anlotinib
|
| label | Anlotinib
|
| Has_Salt_Form | |
| NCI_META_CUI | CL526447
|
| code | C138997
|
| prefixIRI | NCIT:C138997
|
| in_subset | |
| Preferred_Name | Anlotinib
|
| FDA_UNII_Code | GKF8S4C432
|
| Contributing_Source | FDA
|
| CAS_Registry | 1058156-90-3
|
| type | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |